http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 08:01:14 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Grifols+starts+two+Phase+3+trials+to+expand+immunoglobulin+labels/26776956.html <p>Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced that the first patients have been dosed in two separate Phase 3 clinical trials aimed at expanding U.S. label indications for its immunoglobulin therapies, Gamunex-C and Xembify.</p> <p>The SIGMA trial will evaluate Gamunex-C, an intravenous immunoglobulin, in combination with standard-of-care treatment to prevent infections in patients with secondary immunodeficiency caused by blood cancers including Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma. The open-label, single-arm study will enroll 50 participants. The primary efficacy objective is to demonstrate that the rate of serious bacterial infections is less than one per participant per year. Expanding http://www.streetinsider.com/FDA/Grifols+starts+two+Phase+3+trials+to+expand+immunoglobulin+labels/26776956.html Thu, 16 Jul 2026 08:01:14 -0400 A.60001765 GRF GRF-P GRFS O.00303353 O.20738543 http://www.streetinsider.com/FDA/Grifols+starts+two+Phase+3+trials+to+expand+immunoglobulin+labels/26776956.html <p>Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced that the first patients have been dosed in two separate Phase 3 clinical trials aimed at expanding U.S. label indications for its immunoglobulin therapies, Gamunex-C and Xembify.</p> <p>The SIGMA trial will evaluate Gamunex-C, an intravenous immunoglobulin, in combination with standard-of-care treatment to prevent infections in patients with secondary immunodeficiency caused by blood cancers including Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma. The open-label, single-arm study will enroll 50 participants. The primary efficacy objective is to demonstrate that the rate of serious bacterial infections is less than one per participant per year. Expanding http://www.streetinsider.com/FDA/Grifols+starts+two+Phase+3+trials+to+expand+immunoglobulin+labels/26776956.html Thu, 16 Jul 2026 08:01:14 -0400 A.60001765 GRF GRF-P GRFS O.00303353 O.20738543 http://www.streetinsider.com/FDA/Grifols+starts+two+Phase+3+trials+to+expand+immunoglobulin+labels/26776956.html <p>Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced that the first patients have been dosed in two separate Phase 3 clinical trials aimed at expanding U.S. label indications for its immunoglobulin therapies, Gamunex-C and Xembify.</p> <p>The SIGMA trial will evaluate Gamunex-C, an intravenous immunoglobulin, in combination with standard-of-care treatment to prevent infections in patients with secondary immunodeficiency caused by blood cancers including Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma. The open-label, single-arm study will enroll 50 participants. The primary efficacy objective is to demonstrate that the rate of serious bacterial infections is less than one per participant per year. Expanding http://www.streetinsider.com/FDA/Grifols+starts+two+Phase+3+trials+to+expand+immunoglobulin+labels/26776956.html Thu, 16 Jul 2026 08:01:14 -0400 A.60001765 GRF GRF-P GRFS O.00303353 O.20738543 http://www.streetinsider.com/FDA/Grifols+starts+two+Phase+3+trials+to+expand+immunoglobulin+labels/26776956.html <p>Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced that the first patients have been dosed in two separate Phase 3 clinical trials aimed at expanding U.S. label indications for its immunoglobulin therapies, Gamunex-C and Xembify.</p> <p>The SIGMA trial will evaluate Gamunex-C, an intravenous immunoglobulin, in combination with standard-of-care treatment to prevent infections in patients with secondary immunodeficiency caused by blood cancers including Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma. The open-label, single-arm study will enroll 50 participants. The primary efficacy objective is to demonstrate that the rate of serious bacterial infections is less than one per participant per year. Expanding http://www.streetinsider.com/FDA/Grifols+starts+two+Phase+3+trials+to+expand+immunoglobulin+labels/26776956.html Thu, 16 Jul 2026 08:01:14 -0400 A.60001765 GRF GRF-P GRFS O.00303353 O.20738543 http://www.streetinsider.com/FDA/Grifols+starts+two+Phase+3+trials+to+expand+immunoglobulin+labels/26776956.html <p>Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced that the first patients have been dosed in two separate Phase 3 clinical trials aimed at expanding U.S. label indications for its immunoglobulin therapies, Gamunex-C and Xembify.</p> <p>The SIGMA trial will evaluate Gamunex-C, an intravenous immunoglobulin, in combination with standard-of-care treatment to prevent infections in patients with secondary immunodeficiency caused by blood cancers including Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma. The open-label, single-arm study will enroll 50 participants. The primary efficacy objective is to demonstrate that the rate of serious bacterial infections is less than one per participant per year. Expanding http://www.streetinsider.com/FDA/Grifols+starts+two+Phase+3+trials+to+expand+immunoglobulin+labels/26776956.html Thu, 16 Jul 2026 08:01:14 -0400 A.60001765 GRF GRF-P GRFS O.00303353 O.20738543 http://www.streetinsider.com/FDA/Grifols+starts+two+Phase+3+trials+to+expand+immunoglobulin+labels/26776956.html <p>Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced that the first patients have been dosed in two separate Phase 3 clinical trials aimed at expanding U.S. label indications for its immunoglobulin therapies, Gamunex-C and Xembify.</p> <p>The SIGMA trial will evaluate Gamunex-C, an intravenous immunoglobulin, in combination with standard-of-care treatment to prevent infections in patients with secondary immunodeficiency caused by blood cancers including Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma. The open-label, single-arm study will enroll 50 participants. The primary efficacy objective is to demonstrate that the rate of serious bacterial infections is less than one per participant per year. Expanding http://www.streetinsider.com/FDA/Grifols+starts+two+Phase+3+trials+to+expand+immunoglobulin+labels/26776956.html Thu, 16 Jul 2026 08:01:14 -0400 A.60001765 GRF GRF-P GRFS O.00303353 O.20738543 http://www.streetinsider.com/Press+Releases/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html <ul type="disc"><li style="text-align:justify;"><strong><em>One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX</em></strong><strong><em>®</em></strong><strong><em>-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary immunodeficiency</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>A second trial, XPERT, will determine whether Grifols’ subcutaneous Ig, XEMBIFY</em></strong><strong><em>®</em></strong><strong><em> (immune globulin subcutaneous human klhw) is non-inferior to GAMUNEX-C in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Both studies are designed to support U.S. label expansion on these fast-growing Grifols Ig franchise therapies and offer patients more treatment options for their immune system disorders</em></strong><br/></li></ul> <p align="justify">BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), http://www.streetinsider.com/Press+Releases/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html Thu, 16 Jul 2026 08:00:00 -0400 A.60001765 GRF GRF-P GRFS O.00303353 O.20738543 http://www.streetinsider.com/Press+Releases/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html <ul type="disc"><li style="text-align:justify;"><strong><em>One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX</em></strong><strong><em>®</em></strong><strong><em>-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary immunodeficiency</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>A second trial, XPERT, will determine whether Grifols’ subcutaneous Ig, XEMBIFY</em></strong><strong><em>®</em></strong><strong><em> (immune globulin subcutaneous human klhw) is non-inferior to GAMUNEX-C in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Both studies are designed to support U.S. label expansion on these fast-growing Grifols Ig franchise therapies and offer patients more treatment options for their immune system disorders</em></strong><br/></li></ul> <p align="justify">BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), http://www.streetinsider.com/Press+Releases/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html Thu, 16 Jul 2026 08:00:00 -0400 A.60001765 GRF GRF-P GRFS O.00303353 O.20738543 http://www.streetinsider.com/Press+Releases/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html <ul type="disc"><li style="text-align:justify;"><strong><em>One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX</em></strong><strong><em>®</em></strong><strong><em>-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary immunodeficiency</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>A second trial, XPERT, will determine whether Grifols’ subcutaneous Ig, XEMBIFY</em></strong><strong><em>®</em></strong><strong><em> (immune globulin subcutaneous human klhw) is non-inferior to GAMUNEX-C in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Both studies are designed to support U.S. label expansion on these fast-growing Grifols Ig franchise therapies and offer patients more treatment options for their immune system disorders</em></strong><br/></li></ul> <p align="justify">BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), http://www.streetinsider.com/Press+Releases/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html Thu, 16 Jul 2026 08:00:00 -0400 A.60001765 GRF GRF-P GRFS O.00303353 O.20738543 http://www.streetinsider.com/Press+Releases/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html <ul type="disc"><li style="text-align:justify;"><strong><em>One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX</em></strong><strong><em>®</em></strong><strong><em>-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary immunodeficiency</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>A second trial, XPERT, will determine whether Grifols’ subcutaneous Ig, XEMBIFY</em></strong><strong><em>®</em></strong><strong><em> (immune globulin subcutaneous human klhw) is non-inferior to GAMUNEX-C in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Both studies are designed to support U.S. label expansion on these fast-growing Grifols Ig franchise therapies and offer patients more treatment options for their immune system disorders</em></strong><br/></li></ul> <p align="justify">BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), http://www.streetinsider.com/Press+Releases/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html Thu, 16 Jul 2026 08:00:00 -0400 A.60001765 GRF GRF-P GRFS O.00303353 O.20738543 http://www.streetinsider.com/Press+Releases/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html <ul type="disc"><li style="text-align:justify;"><strong><em>One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX</em></strong><strong><em>®</em></strong><strong><em>-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary immunodeficiency</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>A second trial, XPERT, will determine whether Grifols’ subcutaneous Ig, XEMBIFY</em></strong><strong><em>®</em></strong><strong><em> (immune globulin subcutaneous human klhw) is non-inferior to GAMUNEX-C in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Both studies are designed to support U.S. label expansion on these fast-growing Grifols Ig franchise therapies and offer patients more treatment options for their immune system disorders</em></strong><br/></li></ul> <p align="justify">BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), http://www.streetinsider.com/Press+Releases/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html Thu, 16 Jul 2026 08:00:00 -0400 A.60001765 GRF GRF-P GRFS O.00303353 O.20738543 http://www.streetinsider.com/Press+Releases/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html <ul type="disc"><li style="text-align:justify;"><strong><em>One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX</em></strong><strong><em>®</em></strong><strong><em>-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary immunodeficiency</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>A second trial, XPERT, will determine whether Grifols’ subcutaneous Ig, XEMBIFY</em></strong><strong><em>®</em></strong><strong><em> (immune globulin subcutaneous human klhw) is non-inferior to GAMUNEX-C in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Both studies are designed to support U.S. label expansion on these fast-growing Grifols Ig franchise therapies and offer patients more treatment options for their immune system disorders</em></strong><br/></li></ul> <p align="justify">BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), http://www.streetinsider.com/Press+Releases/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html Thu, 16 Jul 2026 08:00:00 -0400 A.60001765 GRF GRF-P GRFS O.00303353 O.20738543 http://www.streetinsider.com/Globe+Newswire/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html <ul type="disc"><li style="text-align:justify;"><strong><em>One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX</em></strong><strong><em>®</em></strong><strong><em>-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary immunodeficiency</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>A second trial, XPERT, will determine whether Grifols’ subcutaneous Ig, XEMBIFY</em></strong><strong><em>®</em></strong><strong><em> (immune globulin subcutaneous human klhw) is non-inferior to GAMUNEX-C in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Both studies are designed to support U.S. label expansion on these fast-growing Grifols Ig franchise therapies and offer patients more treatment options for their immune system disorders</em></strong><br/></li></ul> <p align="justify">BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), http://www.streetinsider.com/Globe+Newswire/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html Thu, 16 Jul 2026 08:00:00 -0400 A.60001765 GRF GRF-P GRFS O.00303353 O.20738543 http://www.streetinsider.com/Globe+Newswire/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html <ul type="disc"><li style="text-align:justify;"><strong><em>One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX</em></strong><strong><em>®</em></strong><strong><em>-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary immunodeficiency</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>A second trial, XPERT, will determine whether Grifols’ subcutaneous Ig, XEMBIFY</em></strong><strong><em>®</em></strong><strong><em> (immune globulin subcutaneous human klhw) is non-inferior to GAMUNEX-C in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Both studies are designed to support U.S. label expansion on these fast-growing Grifols Ig franchise therapies and offer patients more treatment options for their immune system disorders</em></strong><br/></li></ul> <p align="justify">BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), http://www.streetinsider.com/Globe+Newswire/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html Thu, 16 Jul 2026 08:00:00 -0400 A.60001765 GRF GRF-P GRFS O.00303353 O.20738543 http://www.streetinsider.com/Globe+Newswire/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html <ul type="disc"><li style="text-align:justify;"><strong><em>One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX</em></strong><strong><em>®</em></strong><strong><em>-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary immunodeficiency</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>A second trial, XPERT, will determine whether Grifols’ subcutaneous Ig, XEMBIFY</em></strong><strong><em>®</em></strong><strong><em> (immune globulin subcutaneous human klhw) is non-inferior to GAMUNEX-C in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Both studies are designed to support U.S. label expansion on these fast-growing Grifols Ig franchise therapies and offer patients more treatment options for their immune system disorders</em></strong><br/></li></ul> <p align="justify">BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), http://www.streetinsider.com/Globe+Newswire/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html Thu, 16 Jul 2026 08:00:00 -0400 A.60001765 GRF GRF-P GRFS O.00303353 O.20738543 http://www.streetinsider.com/Globe+Newswire/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html <ul type="disc"><li style="text-align:justify;"><strong><em>One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX</em></strong><strong><em>®</em></strong><strong><em>-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary immunodeficiency</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>A second trial, XPERT, will determine whether Grifols’ subcutaneous Ig, XEMBIFY</em></strong><strong><em>®</em></strong><strong><em> (immune globulin subcutaneous human klhw) is non-inferior to GAMUNEX-C in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Both studies are designed to support U.S. label expansion on these fast-growing Grifols Ig franchise therapies and offer patients more treatment options for their immune system disorders</em></strong><br/></li></ul> <p align="justify">BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), http://www.streetinsider.com/Globe+Newswire/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html Thu, 16 Jul 2026 08:00:00 -0400 A.60001765 GRF GRF-P GRFS O.00303353 O.20738543 http://www.streetinsider.com/Globe+Newswire/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html <ul type="disc"><li style="text-align:justify;"><strong><em>One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX</em></strong><strong><em>®</em></strong><strong><em>-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary immunodeficiency</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>A second trial, XPERT, will determine whether Grifols’ subcutaneous Ig, XEMBIFY</em></strong><strong><em>®</em></strong><strong><em> (immune globulin subcutaneous human klhw) is non-inferior to GAMUNEX-C in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Both studies are designed to support U.S. label expansion on these fast-growing Grifols Ig franchise therapies and offer patients more treatment options for their immune system disorders</em></strong><br/></li></ul> <p align="justify">BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), http://www.streetinsider.com/Globe+Newswire/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html Thu, 16 Jul 2026 08:00:00 -0400 A.60001765 GRF GRF-P GRFS O.00303353 O.20738543 http://www.streetinsider.com/Globe+Newswire/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html <ul type="disc"><li style="text-align:justify;"><strong><em>One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX</em></strong><strong><em>®</em></strong><strong><em>-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary immunodeficiency</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>A second trial, XPERT, will determine whether Grifols’ subcutaneous Ig, XEMBIFY</em></strong><strong><em>®</em></strong><strong><em> (immune globulin subcutaneous human klhw) is non-inferior to GAMUNEX-C in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Both studies are designed to support U.S. label expansion on these fast-growing Grifols Ig franchise therapies and offer patients more treatment options for their immune system disorders</em></strong><br/></li></ul> <p align="justify">BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), http://www.streetinsider.com/Globe+Newswire/Grifols+Doses+First+Patients+in+Two+Phase+3+Trials+to+Expand+Indications+of+its+Flagship+Immunoglobulins/26776938.html Thu, 16 Jul 2026 08:00:00 -0400 A.60001765 GRF GRF-P GRFS O.00303353 O.20738543 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Jun+22/26672337.html si-local-file:///var/storage/secattach/20260622/26672337.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Jun+22/26672337.html Mon, 22 Jun 2026 14:18:00 -0400 0RDU GRFS O.00303353 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Jun+22/26672337.html si-local-file:///var/storage/secattach/20260622/26672337.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Jun+22/26672337.html Mon, 22 Jun 2026 14:18:00 -0400 0RDU GRFS O.00303353 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Jun+22/26672337.html si-local-file:///var/storage/secattach/20260622/26672337.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Jun+22/26672337.html Mon, 22 Jun 2026 14:18:00 -0400 0RDU GRFS O.00303353 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Jun+18/26665768.html si-local-file:///var/storage/secattach/20260618/26665768.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Jun+18/26665768.html Thu, 18 Jun 2026 16:00:00 -0400 0RDU GRFS O.00303353 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Jun+18/26665768.html si-local-file:///var/storage/secattach/20260618/26665768.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Jun+18/26665768.html Thu, 18 Jun 2026 16:00:00 -0400 0RDU GRFS O.00303353 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Jun+18/26665768.html si-local-file:///var/storage/secattach/20260618/26665768.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Grifols+SA++++++++++++++++For%3A+Jun+18/26665768.html Thu, 18 Jun 2026 16:00:00 -0400 0RDU GRFS O.00303353 http://www.streetinsider.com/Corporate+News/Grifols+launches+FESILTY+fibrinogen+concentrate+in+the+US/26644496.html <p>Grifols (MCE: GRF, NASDAQ: GRFS) announced the US launch of FESILTY, a fibrinogen concentrate approved by the Food and Drug Administration for treating acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency.</p><p>The FDA approved FESILTY in December for patients with congenital fibrinogen deficiency, including hypo- or afibrinogenemia, but not for dysfibrinogenemia. The treatment addresses a rare inherited condition caused by genetic mutations that impair fibrinogen production or function.</p><p>FESILTY provides a purified fibrinogen concentrate that enables rapid restoration of fibrinogen levels during bleeding events. The product can be stored at room temperature and reconstituted in approximately three minutes, http://www.streetinsider.com/Corporate+News/Grifols+launches+FESILTY+fibrinogen+concentrate+in+the+US/26644496.html Mon, 15 Jun 2026 08:02:13 -0400 GIKLY GRF GRF-P GRFS